Possible new ways in the pharmacological treatment of bipolar disorder and comorbid alcoholism by Azorin, Jean-Michel et al.
© 2010 Azorin et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Neuropsychiatric Disease and Treatment 2010:6 37–46
Neuropsychiatric Disease and Treatment
37
M i N i - r e v i e w
Dovepress
open access to scientific and medical research
Open Access Full Text Article
submit your manuscript | www.dovepress.com
Dovepress 
Possible new ways in the pharmacological 
treatment of bipolar disorder and comorbid 
alcoholism
Jean-Michel Azorin1 
Charles L Bowden2 
ricardo P Garay3 
Giulio Perugi4 
eduard vieta5 
Allan H Young6
1Department of Psychiatry, CHU 
Sainte Marguerite, Marseilles, France; 
2Department of Psychiatry, University 
of Texas Health Science Center, San 
Antonio, TX, USA; 3CNrS-UMr 8162, 
Université Paris-Sud, and Hôpital 
Marie Lannelongue, Le Plessis-
robinson, France; 4vincent P Dole 
Dual Diagnosis Team, Santa Chiara 
and University Hospital, Department 
of Psychiatry, University of Pisa, italy; 
5Clinical institute of Neuroscience, 
Hospital Clinic, University of 
Barcelona, iDiBAPS, CiBer-SAM, 
Barcelona, Spain; 6institute of Mental 
Health, University of British Columbia, 
vancouver, Canada
Correspondence: ricardo P Garay 
46bis, rue du Maréchal Galliéni – 91360 
villemoisson-sur-Orge, France 
Tel +33 1 6904 8034 
Fax +33 1 6904 8034 
email ricardo.garay@orange.fr
Abstract: About half of all bipolar patients have an alcohol abuse problem at some point of 
their lifetime. However, only one randomized, controlled trial of pharmacotherapy (valproate) 
in this patient population was published as of 2006. Therefore, we reviewed clinical trials in 
this indication of the last four years (using mood stabilizers, atypical antipsychotics, and other 
drugs). Priority was given to randomized trials, comparing drugs with placebo or active com-
parator. Published studies were found through systematic database search (PubMed, Scirus, 
EMBASE, Cochrane Library, Science Direct). In these last four years, the only randomized, 
clinically relevant study in bipolar patients with comorbid alcoholism is that of Brown and 
colleagues (2008) showing that quetiapine therapy decreased depressive symptoms in the 
early weeks of use, without modifying alcohol use. Several other open-label trials have been 
generally positive and support the efficacy and tolerability of agents from different classes 
in this patient population. Valproate efficacy to reduce excessive alcohol consumption in 
bipolar patients was confirmed and new controlled studies revealed its therapeutic benefit to 
prevent relapse in newly abstinent alcoholics and to improve alcohol hallucinosis. Topiramate 
deserves to be investigated in bipolar patients with comorbid alcoholism since this compound 
effectively improves physical health and quality of life of alcohol-dependent individuals. In 
conclusion, randomized, controlled research is still needed to provide guidelines for possible 
use of valproate and other agents in patients with a dual diagnosis of bipolar disorder and 
substance abuse or dependence.
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Introduction
In the US, almost half of all bipolar patients have an alcohol abuse problem at some 
point in their lifetime.1–3 Concurrent alcohol abuse disorders have been linked to severe 
disability, increased violence, increased hospitalization, and greater suicide risk.1–3 
However, few treatment trials have been conducted in this population. In 2006, three 
reviews of the literature1–3 showed only one randomized, controlled trial of pharmaco-
therapy (valproate) and raised the hope of more studies coming in the near future. Given 
the importance of the subject, we review here the clinical trials published from 2006 
to the present. Drugs reviewed belong to three therapeutic classes: mood stabilizers, 
atypical antipsychotics, and drugs specifically used for treating alcohol dependence. 
Readers interested in psychotherapeutic approaches can consult the recent studies by 
Weiss and colleagues4,5 and Farren and colleagues.6 Molecular mechanisms of bipolar 
disease and drug action were reviewed by Lan and colleagues,7 Kato,8 and Catapano 
and Manji.9Neuropsychiatric Disease and Treatment 2010:6 38
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Methods
Search strategy
We reviewed recent clinical trials (from the last four years) 
of efficacy and tolerability of drugs in bipolar disorder and 
comorbid alcoholism. A priority was given to randomized tri-
als, comparing drugs with placebo or active comparators.
We compared the following keywords (as article title, 
when possible): “lithium”, “anticonvulsants”, “valproate”, 
“lamotrigine”, topiramate, “gabapentin”, “atypical anti-
psychotics”, “quetiapine”, “aripiprazole”, “risperidone”, 
“olanzapine”, “naltrexone”, or “acamprosate” with: “bipolar” 
and/or “alcohol”, and/or “alcoholism”.
Databases
Published studies were found through systematic search 
of databases (PubMed, Scirus, EMBASE, Cochrane 
Library, Science Direct). We also searched the registers 
of: The Cochrane Central Register of Controlled Trials, 
ClinicalTrials.gov, Current Controlled Trials, International 
Clinical Registry Platform of the World Health Organization, 
CenterWatch, and Afssaps.
Other sources
We consulted the abstracts from recent Annual Meetings of 
the American Academy of Addiction Psychiatry (AAAP) 
and the American Psychiatric Association (APA). A reference 
to these abstracts is given when the studies were presented at 
meetings only. We also checked the references of articles and 
trials, and reviewed main psychiatric journals and guidelines 
for the treatment of patients with bipolar or substance use 
disorders. Finally, we contacted trial authors, other experts, 
and consulted the websites of pharmaceutical companies that 
market active compounds.
Results
Table 1 summarizes the results of recent clinical trials in 
bipolar disease with comorbid alcoholism.
Lithium
Previous data
In 1998, Geller and colleagues10 reported an advantage of 
lithium compared with placebo in improving mood symptoms 
and substance use in a small, six-week, double-blind study 
Table 1 recent clinical trials in bipolar disease with comorbid alcoholism
Study  Design  Drug  Sample (n)  Observation 
period
Effect size 
Sattar16,32 Open label trial valproate 20 SUDP  
(Alcohol n = 10)
24 weeks Halved both, SUD days (BS)  
and YMrS score (BS)
reoux et al17* Double-blind, placebo- 
controlled trial
valproate (v)
Placebo (P)
13 (5 HAP)
14 (7 HAP)
12 weeks relapses: 0 (v) vs  
3 (P) in HAP  
patients (SS)
rubio et al22 Open label trial Lamotrigine 28 24 weeks 30% to 70% reduction in all  
outcome measures (SS)
Brown et al33 randomized, double blind,  
placebo-controlled
Quetiapine (Q) 
Placebo (P)
52
50
12 weeks HrSD: -10.1 (v) vs -9.0 (P)  
(SS). NS for alcohol use
Martinotti et al34 Open label trial Quetiapine 28 MDP  
(BP = 16)
16 weeks SS reductions in all alcohol  
outcome measures (alcohol free 
MDP = 43%)
Davis et al36* randomized, double blind,  
comparative study
risperidone vs  
valproate
30 12 weeks NS differences in alcohol  
outcome measures
Brown et al38 Open label trial Naltrexone 34 16 weeks SS improvement in HrSD  
(-28%), YMrS (-34%) and alcohol  
outcome measures (-50%)
Salloum et al39 randomized, open label  
trial
Naltrexone/valproate vs 
valproate alone
21 More abstinence with naltrexone/   
valproate (71.4%) than with  
valproate alone (43%)
Frye et al37*  Single-blind randomized  
trial
valproate vs olanzapine  50 
 
52 weeks 
 
valproate superior (P = 0.02)  
to olanzapine in reducing alcohol  
relapse in women, but not in men
Notes: *results reported in the form of a meeting abstract. 
Abbreviations: SUDP, patients with substance use disorders; HAP, patients with high anxiety; HrSD, Hamilton rating Scale for Depression; MDP, patients with mood disorders; 
BP, patients with bipolar disorders; SS, statistically significant; BS, borderline statistical significance; NS, nonstatistically significant.Neuropsychiatric Disease and Treatment 2010:6 39
Bipolar disorder and alcoholism Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
of 25 adolescents with bipolar disorder and secondary sub-
stance use.
recent data
To our knowledge, no other randomized trial of lithium in 
bipolar disease with comorbid alcoholism followed the study 
of Geller and colleagues.10
Anticonvulsants
valproate
Previous data
In 1995, Brady and colleagues11,12 first reported preliminary 
evidence for the efficacy of valproate in the acute treatment 
of bipolar episodes complicated by concomitant substance 
dependence (see also Brady and colleagues13). In 2005, 
Salloum and colleagues14 published the results of a random-
ized, double blind trial where valproate was added to lithium 
in 59 alcoholic bipolar I patients. Twelve (44%) of 27 sub-
jects in the valproate group reported heavy drinking days 
compared with 17 (68%) of 25 in the placebo group. Adding 
valproate to lithium halved excessive alcohol consumption 
(measured as the number of heavy drinking days and the 
number of drinks per heavy drinking day).14 Moreover, level 
of gamma-glutamyl transpeptidase, a consequence of recent 
alcohol use was significantly lower in the valproate group 
(-19%) compared with the lithium plus placebo group. Manic 
and depressive symptoms improved equally in both groups. 
Based on these observations,11–14 the American Psychiatric 
Association (APA) supported the use of valproate to treat the 
comorbidity of bipolar disease with alcohol abuse.15
recent data
In 2007, further evidence for valproate efficacy in reduc-
ing excessive alcohol consumption in bipolar patients was 
provided by Sattar,16 who conducted a 24-week open study 
in 20 patients with bipolar disorder comorbid with alcohol 
dependence (n = 10) or other stimulant dependence (n = 10). 
Similarly to Salloum and colleagues,14 subjects halved the 
number of substance use days (17.1 vs 9.7 days) as compared 
with the month before valproate treatment,16 although the dif-
ference was of borderline statistical significance (P = 0.07). 
Patients tolerated valproate well with minimal reports of side 
effects and no liver toxicity was noted.
Reoux and colleagues17 recently found that valproate 
(extended release divalproex sodium) promotes abstinence in 
newly abstinent alcoholics with comorbid mood and anxiety 
disorders. These authors carried out a 12 week, double-blind 
placebo-controlled clinical trial of valproate in 32 of these 
patients. Patients with higher anxiety scores were less likely to 
experience alcohol dependence relapse if in the valproate treat-
ment group (P = 0.017). In addition to promoting abstinence, 
valproate treatment improved psychiatric symptoms in alcohol 
dependent individuals with greater baseline psychiatric symp-
tom severity, particularly mood and anxiety symptoms.17
Side effects
One concern with the use of valproate in actively drinking 
or recovering alcoholics is the potential for serious, although 
rare, hepatic and/or pancreatic side effects.18–21 As docu-
mented out by Frye and Salloum,1 none of the studies com-
pleted to date on valproate in alcohol dependence (withdrawal 
or relapse prevention) or in bipolar disorder with comorbid 
alcoholism have reported such serious adverse events. Most 
of these studies have reported a decrease, rather than an 
increase, in liver function tests, mostly due to a decrease in 
alcohol use. However, care should be taken before a conclu-
sion is reached because the sample sizes of these treatment 
studies were too small to find rare but severe side effects.
Lamotrigine
To our knowledge, no randomized studies of lamotrigine in 
bipolar disease with comorbid alcoholism have been conducted 
so far. In 2006, Rubio and colleagues22 reported the results of 
an open-label trial of lamotrigine in 18 men and 10 women 
diagnosed with alcohol dependence and bipolar disorder 
I (n = 21) or bipolar disorder II (n = 7), with a mean age of 
36.5 years. Lamotrigine was added to the existing medication 
regimens at a dose of 25 mg/day and titrated to a maximum 
dose of 300 mg/day. The concentration of carbohydrate-
deficient transferrin (CDT) was used as an indirect measure 
of alcohol consumption. Statistically significant decreases 
were found for: CDT (-40%, P  0.001), Visual Analog 
Scale for Craving (VASC; -32.5%, P  0.01), drinks per 
week (-67.7%, P  0.01), Hamilton Rating Scale for Depres-
sion (HRSD; -31.4%, P  0.01), Young Mania Rating Scale 
(YMRS; -40.8%, P  0.001) and Brief Psychiatric Rating 
Scale (BPRS; -54.4%, P  0.01) scores. Lamotrigine was well 
tolerated with no dropout subjects due to adverse events.
Topiramate
No randomized studies of topiramate in bipolar disease with 
comorbid alcoholism were found in the literature.
Previous data
In 2002, Guille and Sachs23 reported that topiramate improved 
a comorbid alcohol use abuse condition in four out of seven 
highly refractory bipolar patients. In 2005, Huguelet and Neuropsychiatric Disease and Treatment 2010:6 40
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Morand-Collomb24 reported the case of a 41-year-old bipolar 
patient suffering a severe comorbidity with alcoholism, where 
topiramate treatment allowed him to decrease his alcohol 
intake to an acceptable level.
recent data
To our knowledge, no studies of topiramate in bipolar dis-
ease with comorbid alcoholism have been reported in the 
literature recently.
Gabapentin
No randomized studies of gabapentin in bipolar disease with 
comorbid alcoholism were found in the literature.
Previous data
Perugi and colleagues25 evaluated the effectiveness of gabap-
entin as adjunctive treatment in a sample of 43 subjects with 
bipolar disorder who were resistant to standard mood stabiliz-
ers. Gabapentin was administered as an adjunctive treatment 
for an eight-week period in combination with other mood 
stabilizers, benzodiazepines, antidepressants, and neurolep-
tics. Logistical regression analysis showed that the presence 
of alcohol abuse was associated with positive response.
To our knowledge, no other trials of gabapentin in bipolar 
disease with comorbid alcoholism have been published.
Atypical antipsychotics
Quetiapine
Previous data
Quetiapine is an atypical antipsychotic medication that is 
used to treat the mood symptoms of bipolar disorder.26–28 The 
pilot studies of Brown and colleagues29–31 in small numbers 
of dual-diagnosis patients (n = 17–24) and that of Sattar and 
colleagues32 in nine alcoholic patients with nonpsychotic 
anxiety suggested that quetiapine can reduce alcohol use, 
anxiety, and cravings for alcohol.
recent data
In 2008, Brown and colleagues33 reported the results of 
a randomized, double-blind, placebo-controlled trial of 
quetiapine (add-on therapy) in 115 outpatients with bipolar 
disorder and alcohol abuse or dependence. Patients were 
randomly assigned to 12 weeks of quetiapine (titrated to 
600 mg/day) add-on therapy or placebo. One hundred two 
participants (49% with bipolar I disorder, 82% depressed, 
and 97% with alcohol dependence) returned for at least 
one postbaseline assessment and were used in the random 
regression analysis. Baseline concomitant medications 
and changes in concomitant medications did not differ 
significantly between quetiapine (antidepressants: 38.5%; 
anticonvulsants: 25%; lithium: 13.5%) and placebo (anti-
depressants: 28%; anticonlvulsants: 18%; lithium: 4%) 
groups. No differences were found between the quetiapine 
add-on group and the placebo group on the primary outcome 
measures of alcohol use or the YMRS. However, scores on 
the HRSD decreased significantly more in the quetiapine 
than in the placebo group (P  0.05). The between-group 
difference was largely due to differences in HRSD scores 
during the first six weeks of the trial, with the placebo 
group showing greater improvement during the second 
half of the trial.33
Martinotti and colleagues34 recently conducted an open-
label 16 week study of quetiapine on 28 alcohol-dependent 
subjects with high levels of mood and behavioral instabil-
ity, including 16 patients with bipolar disorders. Quetiap-
ine significantly decreased alcohol consumption (43% of 
patients remained totally alcohol-free for the duration of 
the study), craving for alcohol, and psychiatric symptoms 
intensity (HDRS and BPRS), maintaining a good level of 
tolerability.34
Aripiprazole
Aripiprazole is another atypical antipsychotic used to treat 
mainly manic symptoms of bipolar disorder. To our knowl-
edge, no randomized studies of aripiprazole in bipolar disor-
ders with comorbid alcoholism have been conducted so far.
Previous data
In 2005, Brown and colleagues35 conducted an open-label, 
pilot trial with aripiprazole in 20 antipsychotic-treated 
patients with bipolar or schizoaffective disorder and cur-
rent substance abuse. Patients were switched to open-label 
aripiprazole using an overlap and taper method. Psychiatric 
symptoms, side effects, and substance use and craving were 
assessed over 12 weeks. Significant baseline-to-exit improve-
ment in HRSD (P = 0.002), YMRS (P = 0.021), and BPRS 
(P = 0.000) scores were observed without a significant change 
in antipsychotic-induced side effect scales. In 17 participants 
with current alcohol dependence, significant reductions in 
dollars spent on alcohol (P = 0.042) and alcohol craving 
(P = 0.003) were found. In nine participants with cocaine-
related disorders, significant reductions in cocaine craving 
(P = 0.014), but not use, were found.
recent data
To our knowledge, no other studies of aripiprazole in bipolar 
disorders with comorbid alcoholism were conducted since 
the one of Brown and colleagues.35Neuropsychiatric Disease and Treatment 2010:6 41
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risperidone
Davis and colleagues36 recently conducted a randomized, 
double blind 12-week trial with valproate extended release (ER) 
vs. risperidone monotherapy in 30 bipolar I and II patients with 
active substance use disorder (SUD) within the past 30 days. 
No significant differences between groups were found for 
the number of days until heavy SUD relapse, time to relapse, 
percentage days of SUD use, or percentage days sober.
Olanzapine
In 2006, Frye and colleagues37 conducted a 52-week single-
blind randomized study of valproate versus olanzapine for 
alcohol abuse relapse prevention in 50 actively drinking 
bipolar disease patients. Valproate was found superior 
(P = 0.02) to olanzapine in reducing the rate of relapse to 
alcoholism (defined as return to hazardous drinking) in 
women, although not in men.37
Drugs specifically used for treating 
alcohol dependence
Naltrexone
Naltrexone is effective for alcohol dependence, but its safety 
and efficacy are not established in patients with bipolar disor-
der and alcohol dependence. Brown and colleagues38 recently 
reported the results of a 16-week, open-label, add-on pilot 
study of naltrexone conducted in 34 outpatients with bipolar 
disorder and alcohol dependence. Assessments included the 
17-item HRSD, YMRS, BPRS and an alcohol-craving scale. 
Alcohol use was quantified. Significant improvement was 
observed in the HRSD (-28%), YMRS (-34%), number of 
drinks in the past two weeks (-50%), and alcohol craving 
(-49%). Naltrexone was well tolerated.
Salloum and colleagues39 conducted a randomized, 
open-label study to examine the utility of combined phar-
macotherapy of valproate/naltrexone vs valproate only in 
decreasing alcohol use in patients with comorbid bipolar 
disorder and alcohol dependence. Twenty-one subjects were 
included and followed for eight weeks. All but one (86%) 
of the valproate/naltrexone group completed the study as 
opposed to three (43%) of the valproate-only group. The 
majority 5/7 (71.4%) of the combined group subjects main-
tained abstinence throughout the study compared to 3/7 
(43%) in the valproate group. The valproate/naltrexone group 
compared to the valproate-only group had: (i) an advantage in 
percentage days abstinent, (ii) a somewhat lower percentage 
of heavy drinking, and (iii) an advantage on final outcomes 
for alcohol craving, depressive symptoms, sleep disturbance, 
and functioning.39
Other drugs used for treating  
alcohol dependence
To our knowledge, no trials of acamprosate or other drugs 
used for treating alcohol dependence in bipolar disease with 
comorbid alcoholism have been published.
Discussion
The treatment of patients with bipolar disorder and alcohol 
use disorder is a major public health concern. However, few 
well designed clinical trials have been conducted in this 
population. Indeed, since Salloum and colleagues14 reported 
that adjunctive valproate reduces excessive alcohol consump-
tion in bipolar patients, the only other randomized study 
with a clinically important result is that quetiapine therapy 
was associated with a statistically significant decrease in 
depressive symptoms, at least in the early weeks of use, but 
not alcohol use, in patients with bipolar disorder and alcohol 
dependence.33
The optimal therapeutic goals of excessive alcohol drink-
ing are alcohol withdrawal coupled with relapse prevention. 
Well controlled trials in alcoholic patients (mostly without 
bipolar disease) showed that valproate is of therapeutic ben-
efit in both alcohol withdrawal and relapse prevention. These 
results deserve to be mentioned since they can explain, at 
least in part, the therapeutic benefit of valproate in bipolar 
disease with comorbid alcoholism.
Alcohol withdrawal
Reoux and colleagues40 conducted a randomized, double-
blind, placebo-controlled trial of valproate in 36 hospital-
ized patients experiencing moderate alcohol withdrawal. 
All subjects received a baseline dose of oxazepam and 
had additional oxazepam available as a rescue medication. 
Valproate significantly improved alcohol withdrawal course 
and significantly reduced the use of oxazepam. Group dif-
ferences seemed primarily driven by those subjects who 
experienced symptoms above threshold level after 12 hours. 
The progression in severity of withdrawal symptoms was also 
significantly greater in the placebo group.
relapse prevention
An open randomized trial pilot study by Longo and col-
leagues41 suggested relapse prevention by valproate in 
16 alcohol-dependent patients randomized to receive a stan-
dard benzodiazepine detoxification, valproate detoxification, 
or valproate detoxification with the maintenance treatment. 
Symptom reduction occurred more rapidly and consistently 
in the valproate treated patients than in the benzodiazepine Neuropsychiatric Disease and Treatment 2010:6 42
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control group, and at six-week follow up a greater percentage 
of patients in the valproate maintenance group were com-
pletely abstinent than either detox-only group.
Alcohol hallucinosis
In 2008, Aliyev and Aliyev42 reported the results of a 10-day 
randomized, double-blind, placebo-controlled study of 
valproate in 40 patients with acute alcohol hallucinosis. 
Patients were randomized to valproate 3000 mg/day (n = 20) 
or placebo (n = 20). Valproate-treated patients improved 
significantly more than placebo-treated patients in Clinical 
Global Improvement (CGI; P  0.001) and in Positive and 
Negative Syndrome Scale subscale for verbal hallucinosis 
(PANSS; P  0.001).
Although most studies of valproate in bipolar disorder 
with comorbid alcoholism or in alcohol dependence have 
reported improvement rather than worsening in liver function 
tests, for the present, when valproate is employed in patients 
with bipolar disorder comorbid with alcohol dependence, 
hepatic function should be assessed prior to the start of the 
treatment and at regular intervals thereafter and patients 
should monitoring for symptoms suggestive of liver toxicity. 
Due to the risks of fetal abnormalities from first trimester 
use of valproate, specialist advice is recommended when 
considering valproate use in women of child-bearing age.
Johnson and colleagues43,44 recently found that topiramate 
was efficient in reducing alcohol consumption in alcohol-
dependent subjects. These authors conducted a 17-site, 
14-week, double-blind, randomized controlled trial of topira-
mate (up to 300 mg/day) vs placebo in 371 alcohol-dependent 
subjects (without a current Axis I psychiatric diagnosis on the 
DSM-IV other than alcohol, nicotine, or caffeine dependence) 
who received weekly adherence enhancement therapy.43,44 
Treating all dropouts as relapse to baseline, topiramate was 
more efficacious than placebo at reducing the percentage of 
heavy drinking days from baseline to week 14.43 Moreover, 
topiramate was more efficacious than placebo in reducing 
liver enzyme levels.44 Topiramate compared with placebo, 
significantly decreased obsessional thoughts and compul-
sions about using alcohol, increased subjects’ psychosocial 
well-being, and improved some aspects of quality of life, 
thereby diminishing the risk of relapse and longer-term 
negative outcomes.44 Conversely, four randomized, placebo-
controlled trials of topiramate monotherapy were recently 
conducted in adults with acute manic or mixed episodes of 
bipolar I disorder.45 These trials showed no efficacy of topi-
ramate against mania exacerbation or treatment-emergent 
depression.45
Given the promising results of the well-controlled trial of 
topiramate in alcohol-dependent individuals by Johnson and 
colleagues43,44 (improvement of physical health and quality of 
life with topiramate treatment) this compound deserves to be 
investigated in bipolar disorder and alcohol dependence. The 
therapeutic benefit of topiramate in alcohol-dependence may 
be due to its anticonvulsant properties since other controlled 
studies revealed that valproate is of therapeutic benefit in 
acute alcohol withdrawal,40 that it prevents relapse in newly 
abstinent alcoholics17 and improves alcohol hallucinosis.42 
Moreover, carbamazepine seems also effective to reduce 
alcohol withdrawal symptoms and prevent relapse.1
A randomized, double-blind, placebo-controlled trial 
of gabapentin in 90 alcohol-dependent subjects46 showed a 
significant reduction in both number of drinks per day and 
mean percentage of heavy drinking days, and an increase 
in the percentage of days of abstinence, compared to the 
placebo group. Conversely, the few randomized controlled 
trials designed to investigate the efficacy of gabapentin in 
treating bipolar disorder have concluded that there is no sig-
nificant difference in the effects of the drug compared with 
placebo.47 This may explain why the preliminary study in 
2002 by Perugi and colleagues25 in bipolar alcoholic patients 
was not followed by others.
The open label trials of Brown and colleagues38 and 
Salloum and colleagues39 suggest that added naltrexone is 
effective against alcohol use disorders in bipolar patients. 
Therefore, well controlled studies are required to further 
investigate the efficacy of naltrexone, alone or in combina-
tion with mood stabilizers.
Martinotti and colleagues48 showed that aripiprazole is 
as efficient as naltrexone in reducing alcohol use in alcohol-
dependent subjects. As for craving scores, patients treated 
with naltrexone showed a better outcome.48 Moreover, Anton 
and colleagues49 found more positive subjective treatment 
effects and less overall severity of alcohol dependence in 
subjects treated with aripiprazole as compared with placebo. 
Finally, Brown and colleagues35 found significant reductions 
in dollars spent on alcohol and alcohol craving by aripipra-
zole in bipolar (or schizoaffective) alcoholic patients. These 
results suggest that the efficacy of aripiprazole in alcohol use 
disorders of bipolar patients should be further investigated.
The preliminary small study with lithium reported by 
Geller and colleagues10 in 1998 was not followed by other 
studies in larger number of subjects. One reason can be that 
lithium carbonate was found ineffective in decreasing alcohol 
consumption in a large multicenter, double-blind, placebo-
controlled Veterans Affairs trial.50 This study, conducted Neuropsychiatric Disease and Treatment 2010:6 43
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in 457 male alcoholics either without depression or with 
a history of major depression, current major depression, 
or mood disorder found no significant differences between 
alcoholics who took lithium and those who took placebo for 
the following outcome measures: number of alcoholics absti-
nent, number of days of drinking, number of alcohol-related 
hospitalizations, changes in rating of severity of alcoholism, 
and change in severity of depression.50 In this study, lithium 
treatment did not affect the course of alcoholism in either 
depressed or nondepressed alcoholics.50
Another reason explaining the lack of recent lithium 
trials in bipolar disease with comorbid alcoholism may be 
that lithium is often ineffective in bipolar variants such as 
dysphoric, mixed, or rapid cycling, which are overrepresented 
among bipolar alcoholic patients.14,51
Understanding the molecular mechanisms of dis-
ease strongly helps the design of new pharmacological 
agents. In the past, some reports suggested that a gamma-
aminobutyric acid (GABA) deficit was involved in the 
pathogenesis of both bipolar disorder52,53 and alcoholism54 
(and valproate increases central GABAergic activity55,56), 
but such studies are no longer conducted. Indeed, multiple 
neurotransmitter and neuropeptide G protein-coupled 
receptors (in frontal cortex and limbic-related regions, 
such as the hippocampus, hypothalamus, and brainstem) 
likely underly the complex clinical picture of bipolar dis-
order.9 Moreover, the relation with the biochemical and 
physiopathological mechanisms of alcoholism is unclear. 
Valproate or quetiapine mechanisms in bipolar disorder 
with comorbid alcoholism remain as open question which 
deserves further investigation.
Patients who show response to a certain treatment may 
represent a genetically more homogeneous subgroup of 
bipolar disorders particularly if this subgroup is character-
ized by specific comorbidity (as addiction). Association and 
linkage studies of candidate genes involved in GABAergic 
neurotransmission in valproate-responsive alcoholics/bipolar 
disorders should be developed in the future.
Advances in clinical and epidemiological 
aspects
Although the clinical and epidemiological aspects of bipo-
lar disorder in comorbidity with alcoholism are beyond 
the scope of this review, recent advances in such areas can 
be useful to design future trials. Of particular interest are 
studies investigating patient subtypes and their therapeutic 
responses. Pacchiaroti and colleagues57 recently reported that 
bipolar patients with bipolar disorder I or II whose mood 
symptomatology onset was preceded by substance/alcohol 
use (n = 145) showed fewer total hypomanic and depres-
sive episodes and were poorly compliant to treatment, as 
compared with bipolar patients whose first mood episode 
was unrelated to substance use (n = 144). The authors con-
cluded that bipolar disorder preceded by substance misuse 
may represent a clinically milder subtype of bipolar illness 
and might be more early targeted by primary prevention with 
programmes focused on substance misuse.57
Haro and colleagues58 identified three groups of patients 
with acute mania: “typical mania” (59% of patients); “psy-
chotic mania” (27%) with more severe mania and presence 
of psychotic symptoms; and “dual mania” (13%) with a high 
proportion of substance abuse. Psychotic and dual mania 
predicted poorer outcome in terms of psychosis comorbidity 
and overall bipolar and mania severity, while dual mania addi-
tionally predicted poorer outcome of alcohol and substance 
abuse.59 Worse social outcomes were observed for both dual 
and psychotic mania.59
In 2007, Merikangas and colleagues60 reported the first 
prevalence estimates of the bipolar spectrum in a probabil-
ity sample of the United States. Lifetime (and 12-month) 
prevalence estimates were 1.0% for bipolar disorder I, 1.1% 
for bipolar disorder II, and 2.4% for subthreshold bipolar 
disorder.60 Most bipolar patients received lifetime profes-
sional treatment for emotional problems, but use of antimanic 
medication was uncommon, especially in general medical 
settings and subthreshold bipolar disorder.60
In 2008, Angst and associates61 estimated the respective 
risks posed by the different bipolar subtypes for the subse-
quent development of substance use disorders. Six waves of 
direct diagnostic interviews were administered to a sample of 
591 young adults during a 20-year period. Individuals having 
manic symptoms were at significantly greater risk for the later 
onset of alcohol abuse/dependence, cannabis use and abuse/
dependence, and benzodiazepine use and abuse/dependence. 
Bipolar II disorder predicted both alcohol abuse/dependence 
and benzodiazepine use and abuse/dependence. In contrast, 
major depression was predictive only of later benzodiazepine 
abuse/dependence.
Finally, it is important to recall that bipolar disorder is 
frequently underdiagnosed in the clinical population, lead-
ing to overuse of antidepressants and underuse of mood 
stabilizers. Recently, Albanese and colleagues62 reported that 
bipolar disorders are frequently underdiagnosed in substance-
dependent subjects. These authors found that bipolar disorder 
had not been previously diagnosed in approximately 50% of 
a sample of Caucasian males in a substance abuse population Neuropsychiatric Disease and Treatment 2010:6 44
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who were diagnosed with bipolar disorder upon admission 
to an inpatient substance abuse program.
Guidelines and patient management
Based on the results from the study of Salloum and col-
leagues,14 the APA supported the use of valproate to treat the 
comorbidity of bipolar disease with alcohol abuse.15 However, 
due to the relative absence of clinical guidelines on patient 
selection and implementation of regimens, clear guidelines 
and recommendations are lacking. Based on published data 
and personal experience, Brousse and colleagues63 recently 
suggested tentative treatment guidelines. Table 2 summarizes 
such recommendations.
When possible, alcohol withdrawal without relapse is the 
therapeutic goal.63 Abstinence is recommended when starting 
a treatment with mood stabilizer in a bipolar patient undergo-
ing excessive alcohol drinking, particularly when the patient 
presents with mood symptoms. If possible, mood stabilizer 
treatment should be initiated under hospital control, until 
mood stabilization (around 1 month) and/or relapse preven-
tion (around 6 months) is achieved. Finally, psychoeducation 
should be given about both alcohol dependence and bipolar 
disorders and, their complex interaction, including the dangers 
consequent to alcohol abuse and symptoms of relapse.63
Conclusions and future directions
In these last three years, the only randomized, clinically 
relevant study in bipolar patients with comorbid alcoholism 
is that of Brown and colleagues33 showing that quetiapine 
therapy decreased depressive symptoms in the early weeks 
of use, without modifying alcohol use. Valproate efficacy to 
reduce excessive alcohol consumption in bipolar patients14 
was confirmed16 and new controlled studies revealed its 
therapeutic benefit to prevent relapse in newly abstinent 
alcoholics17 and to improve alcohol hallucinosis.42
Several compounds deserve to be investigated for their 
efficacy to reduce alcohol use disorders in bipolar patients:
•  Topiramate. This compound effectively improves 
physical health and quality of life of alcohol-dependent 
individuals.43,44 Moreover, a pilot study23 and a case 
report24 suggests its efficacy to reduce alcohol use disor-
ders in bipolar patients.
•  Naltrexone. Well controlled studies are required to fur-
ther investigate the efficacy of naltrexone, alone or in 
combination with mood stabilizers, against alcohol use 
disorders in bipolar patients.38,39
•  Aripiprazole. Aripiprazole seems efficient in reducing 
alcohol use disorders in alcohol-dependent subjects48,49 
and even in bipolar patients. This should be confirmed 
in well controlled trials.
While the results have been generally positive and sup-
port the efficacy and tolerability of several agents from 
different classes in patients with a dual diagnosis of bipolar 
disorder and substance abuse or dependence, randomized, 
controlled research is needed to confirm these findings and 
provide conclusive results and guidelines for possible use 
of the agents.
Disclosures
The authors report no conflicts of interest in this work.
References
  1.  Frye MA, Salloum IM. Bipolar disorder and comorbid alcoholism: 
prevalence rate and treatment considerations. Bipolar Disord. 
2006;8:677–685.
  2.  Vornik LA, Brown ES. Management of comorbid bipolar disorder and 
substance abuse. J Clin Psychiatry. 2006;67:24–30.
  3.  Brown ES. Management of comorbid bipolar disorder and substance 
abuse. J Clin Psychiatry. 2006;67(Suppl 7):24–30.
  4.  Weiss RD. Treating patients with bipolar disorder and substance 
dependence: Lessons learned. J Subst Abuse Treat. 2004;27: 
307–312.
  5.  Weiss RD, Griffin ML, Jaffee WB, et al. A “community-friendly” ver-
sion of integrated group therapy for patients with bipolar disorder and 
substance dependence: A randomized controlled trial. Drug Alcohol 
Depend. 2009;104:212–219.
  6.  Farren CK, McElroy S. Treatment response of bipolar and unipolar 
alcoholics to an inpatient dual diagnosis program. J Affect Disord. 
2008;106:265–272.
  7.  Lan MJ, McLoughlin GA, Griffin JL, et al. Metabonomic analysis identi-
fies molecular changes associated with the pathophysiology and drug 
treatment of bipolar disorder. Mol Psychiatry. 2008;14:269–279.
  8.  Kato T. Molecular neurobiology of bipolar disorder: a disease of ‘mood-
stabilizing neurons’? Trends Neurosci. 2008;31:495–503.
Table 2 recommendations for the management of bipolar disorder in comorbidity with alcoholism63
•    in case of alcohol abuse, reduce alcohol consumption to normal when possible. in case of failure or in case of alcohol-dependence, proceed to 
alcohol withdrawal.
•  Following alcohol withdrawal, alcohol-dependence and bipolar disorder should be simultaneously treated. Use valproate as first treatment choice.
•  inform the patient about the interaction between alcoholism and bipolar disorder, insisting about the depressive risk.
•  rationalize the myth of alcohol as auto-medication.63
•  Provide psycho-education about situations favoring mood disorder episodes or substance use.
•  evaluate treatment discontinuation or misuse.Neuropsychiatric Disease and Treatment 2010:6 45
Bipolar disorder and alcoholism Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
  9.  Catapano LA, Manji HK. G protein-coupled receptors in major 
psychiatric disorders. Biochim Biophys Acta. 2007;1768:976–993.
10.  Geller B, Cooper TB, Sun K, et al. Double blind and placebo-
controlled study of lithium for adolescent bipolar disorders with 
secondary substance dependency. J Am Acad Child Adolesc Psychiatry. 
1998;37:171–178.
11.  Brady KT, Sonne SC. The relationship between substance abuse and 
bipolar disorder. J Clin Psychiatry. 1995;56(Suppl 3):19–24.
12.  Brady KT, Sonne SC, Anton R, Ballenger JC. Valproate in the treatment 
of acute bipolar affective episodes complicated by substance abuse: 
a pilot study. J Clin Psychiatry. 1995;56:118–121.
13.  Brady KT, Myrick H, Henderson S, Coffey SF. The use of divalproex 
in alcohol relapse prevention: a pilot study. Drug Alcohol Depend. 
2002;67:323–330.
14.  Salloum IM, Cornelius JR, Daley DC, Kirisci L, Himmelhoch JM, 
Thase ME. Efficacy of valproate maintenance in patients with bipolar 
disorder and alcoholism: a double-blind placebo-controlled study. Arch 
Gen Psychiatry. 2005;62:37–45.
15.  American Psychiatric Association. Practice guideline for the treatment 
of patients with substance use disorders, 2nd edition. 2006. Available 
from: http://wwwpsychorg/psych_pract/treatg/pg/prac_guide.cfm. 
Accessed on August 10, 2009.
16.  Sattar SP. Valproate in the treatment of bipolar disorder and co-
morbid substance abuse: a 24-week open lable trial. Biol Psychiatry. 
2007;61:46S.
17.  Reoux JP, Malte CA, Farr CL, Ferguson LC, Saxon AJ, editors. 
Controlled trial of extended release divalproex sodium in alcohol 
dependent patients with subsyndromal psychiatric symptoms. 18Th 
annual meeting and symposium of the American Academy of Addic-
tion Psychiatry (AAAP); 2007; Hotel Del Coronado, Coronado, CA, 
USA.
18.  Bryant AE III, Dreifuss FE. Valproic acid hepatic fatalities. III. US 
experience since 1986. Neurology. 1996;46:465–469.
19.  Jimenez-Rodriguezvila M, Caro-Patón A, Conde M, et al. Side-effects 
of sodium valproate, mainly related to its hepatic and pancreatic toxicity. 
Int J Clin Pharmacol Res. 1986;6:217–224.
20.  Dreifuss FE, Santilli N, Langer DH, Sweeney KP, Moline KA, 
Menander KB. Valproic acid hepatic fatalities: a retrospective review. 
Neurology. 1987;37:379–385.
21.  Dreifuss FE, Langer DH. Hepatic considerations in the use of antiepi-
leptic drugs. Epilepsia. 1987;28(Suppl 2):S23–S29.
22.  Rubio G, López-Muñoz F, Alamo C. Effects of lamotrigine in patients 
with bipolar disorder and alcohol dependence. Bipolar Disord. 
2006;8:283–293.
23.  Guille C, Sachs G. Clinical outcome of adjunctive topiramate treatment 
in a sample of refractory bipolar patients with comorbid conditions. 
Prog Neuropsychopharmacol Biol Psychiatry. 2002;26:1035–1039.
24.  Huguelet P, Morand-Collomb S. Effect of topiramate augmentation 
on two patients suffering from schizophrenia or bipolar disorder with 
comorbid alcohol abuse. Pharmacol Res. 2005;52:392–394.
25.  Perugi G, Toni C, Frare F, et al. Effectiveness of adjunctive gabapentin 
in resistant bipolar disorder: is it due to anxious-alcohol abuse comor-
bidity? J Clin Psychopharmacol. 2002;22:584–591.
26.  Vieta E, Calabrese JR, Goikolea JM, Raines S, Macfadden W. Que-
tiapine monotherapy in the treatment of patients with bipolar I or II 
depression and a rapid-cycling disease course: a randomized, double-
blind, placebo-controlled study. Bipolar Disord. 2007;9:413–425.
27.  Calabrese JR, Keck PE Jr, Macfadden W, et al. A randomized, double-
blind, placebo-controlled trial of quetiapine in the treatment of bipolar I 
or II depression. Am J Psychiatry. 2005;162:1351–1360.
28.  Thase ME, Macfadden W, Weisler RH, et al; BOLDER II Study Group. 
Efficacy of quetiapine monotherapy in bipolar I and II depression: 
a double-blind, placebo-controlled study (the BOLDER II study). J 
Clin Psychopharmacol. 2006;26:600–609.
29.  Longoria J, Brown ES, Perantie DC, Bobadilla L, Nejtek VA. Quetiapine 
for alcohol use and craving in bipolar disorder. J Clin Psychopharmacol. 
2004;24:101–102.
30.  Brown ES, Nejtek VA, Perantie DC, Bobadilla L. Quetiapine in bipolar 
disorder and cocaine dependence. Bipolar Disord. 2002;4:406–411.
31.  Brown ES, Nejtek VA, Perantie DC, Rajan Thomas N, Rush AJ. Cocaine 
and amphetamine use in patients with psychiatric illness: a randomized 
trial of typical antipsychotic continuation or discontinuation. J Clin 
Psychopharmacol. 2003;23:384–388.
32.  Sattar SP, Schultz SK, Arndt S, Soundy T, Petty F. Long-term adjunctive 
quetiapine may reduce substance use–a preliminary retrospective study. 
South Dakota Med. 2007;60:439–441.
33.  Brown ES, Garza M, Carmody TJ. A randomized, double-blind, 
placebo-controlled add-on trial of quetiapine in outpatients with bipo-
lar disorder and alcohol use disorders. J Clin Psychiatry. 2008;69: 
701–705.
34.  Martinotti G, Andreoli S, Di Nicola M, Di Giannantonio M, 
Sarchiapone M, Janiri L. Quetiapine decreases alcohol consumption, 
craving, and psychiatric symptoms in dually diagnosed alcoholics. 
Human Psychopharmacol Clin Exp. 2008;23:417–424.
35.  Brown ES, Jeffress J, Liggin JD, Garza M, Beard L. Switching outpa-
tients with bipolar or schizoaffective disorders and substance abuse 
from their current antipsychotic to aripiprazole. J Clin Psychiatry. 
2005;66:756–760.
36.  Davis LL, Li X, Garner C, Biladeau J, Ustinov Y, Uezato A. Divalproex 
ER versus risperidone for bipolar disorder with comorbid substance 
use disorder. Washington, DC: 161st Annual Meeting of the American 
Psychiatric Association; May 3–8, 2008.
37.  Frye MA, Chirichigno JW, McKowen J, et al. A single-blind evaluation 
of divalproex sodium vs olanzapine for alcohol abuse relapse preven-
tion in bipolar disorder. Don Cesar Beach Resort, FL: AAAP Annual 
Meeting and Symposium Dec 7–10, 2006.
38.  Brown ES, Beard L, Dobbs L, Rush AJ. Naltrexone in patients 
with bipolar disorder and alcohol dependence. Depress Anxiety. 
2006;23:492–495.
39.  Salloum IM, Douaihy A, Cornelius JR, Daley DC, Kelly TM, Kirisci L. 
Open label randomized pilot study of combined naltrexone and valproate 
in bipolar alcoholics. Alcohol Clin Exp Res. 2006;30:140A.
40.  Reoux JP, Saxon AJ, Malte CA, Baer JS, Sloan KL. Divalproex sodium 
in alcohol withdrawal: a randomized double-blind placebo-controlled 
clinical trial. Alcohol Clin Exp Res. 2001;25:1324–1329.
41.  Longo LP, Campbell T, Hubatch S. Divalproex sodium (Depakote) 
for alcohol withdrawal and relapse prevention. J Addict Dis. 2002; 
21:55–64.
42.  Aliyev ZN, Aliyev NA. Valproate treatment of acute alcohol hal-
lucinosis: a double-blind, placebo-controlled study. Alcohol Alcohol. 
2008;43:456–459.
43.  Johnson BA, Rosenthal N, Capece JA, et al. Topiramate for treat-
ing alcohol dependence: a randomized controlled trial. JAMA. 
2007;298:1641–1651.
44.  Johnson BA, Rosenthal N, Capece JA, et al; Topiramate for Alcoholism 
Advisory Board; Topiramate for Alcoholism Study Group. Improvement 
of physical health and quality of life of alcohol-dependent individuals 
with topiramate treatment: US multisite randomized controlled trial. 
Arch Intern Med. 2008;168:1188–1199.
45.  Kushner SF, Khan A, Lane R, Olson WH. Topiramate monotherapy in 
the management of acute mania: results of four double-blind placebo-
controlled trials. Bipolar Disord. 2006;8:15–27.
46.  Furieri FA, Nakamura-Palacios EM. Gabapentin reduces alcohol con-
sumption and craving: a randomized, double-blind, placebo-controlled 
trial. J Clin Psychiatry. 2007;68:1691–1700.
47.  Mack A. Examination of the evidence for off-label use of gabapentin. 
J Manag Care Pharm. 2003;9:559–568.
48.  Martinotti G, Di Nicola M, Di Giannantonio M, Janiri L. Aripiprazole in 
the treatment of patients with alcohol dependence: a double-blind, com-
parison trial vs naltrexone. J Psychopharmacol. 2009;23:123–129.
49.  Anton RF, Kranzler H, Breder C, Marcus RN, Carson WH, Han J. 
A randomized, multicenter, double-blind, placebo-controlled study 
of the efficacy and safety of aripiprazole for the treatment of alcohol 
dependence. J Clin Psychopharmacol. 2008;28:5–12.Neuropsychiatric Disease and Treatment 2010:6
Neuropsychiatric Disease and Treatment
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journal
Neuropsychiatric Disease and Treatment is an international, peer-
reviewed journal of clinical therapeutics and pharmacology focusing on 
concise rapid reporting of clinical or pre-clinical studies on a range of 
neuropsychiatric and neurological disorders. This journal is indexed on 
PubMed Central, the ‘PsycINFO’ database and CAS, and is the official 
journal of The International Neuropsychiatric Association (INA). The 
manuscript management system is completely online and includes a 
very quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
46
Azorin et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
50.  Dorus W, Ostrow DG, Anton R, et al. Lithium treatment of depressed 
and nondepressed alcoholics. JAMA. 1989;262:1646–1652.
51.  Dilsaver SC, Swann AC, Shoaib AM, Bowers TC. The manic syndrome: 
factors which may predict a patient’s response to lithium, carbamazepine 
and valproate. J Psychiatry Neurosci. 1993;18:61–66.
52.  Petty F. GABA and mood disorders: a brief review and hypothesis. 
J Affective Disord. 1995;34:275–281.
53.  Brambilla P, Perez J, Barale F, Schettini G, Soares JC. GABAergic 
dysfunction in mood disorders. Mol Psychiatry. 8:721–737.
54.  Enoch MA. The role of GABAa receptors in the development of alco-
holism. Pharmacol Biochem Behav. 2008;90:95–104.
55.  Vargas C, Tannhauser M, Barros HM. Dissimilar effects of lithium and 
valproic acid on GABA and glutamine concentrations in rat cerebro-
spinal fluid. Gen Pharmacol. 1998;30:601–604.
56.  Zimmer R, Teelken AW, Gündürewa M, Rüther E, Cramer H. Effect of 
sodium-valproate on CSF GABA, cAMP, cGMP and homovanillic acid 
levels in men. Br Res Bull. 1980;5(Suppl 2):585–588.
57.  Pacchiarotti I, Marzo SD, Colom F, Sanchez-Moreno J, Vieta E. Bipolar 
disorder preceded by substance abuse: A different phenotype with not 
so poor outcome? World J Biol Psychiatry. 2007;13:1–8.
58.  Haro JM, van Os J, Vieta E, Reed C, Lorenzo M, Goetz I; EMBLEM 
Advisory Board. Evidence for three distinct classes of ‘typical’, 
‘psychotic’ and ‘dual’ mania: results from the EMBLEM study. Acta 
Psychiatr Scand. 2006;113:112–120.
59.  van Rossum I, Haro JM, Tenback D, et al. Stability and treatment out-
come of distinct classes of mania. Eur Psychiatry. 2008;23:360–367.
60.  Merikangas KR, Akiskal HS, Angst J, et al. Lifetime and 12-month 
prevalence of bipolar spectrum disorder in the National Comorbidity 
Survey replication. Arch Gen Psychiatry. 2007;64:543–552.
61.  Merikangas KR, Herrell R, Swendsen J, Rössler W, Ajdacic-Gross V , 
Angst J. Specificity of bipolar spectrum conditions in the comorbidity 
of mood and substance use disorders: results from the Zurich cohort 
study. Arch Gen Psychiatry. 2008;65:47–52.
62.  Albanese MJ, Clodfelter RC Jr, Pardo TB, Ghaemi SN. Underdiagnosis 
of bipolar disorder in men with substance use disorder. J Psychiatr 
Pract. 2006;12:124–127.
63.  Brousse G, Garay RP, Benyamina A. Management of comorbid bipolar 
disorder and alcohol dependence. Presse Med. 2008;37:1132–1137.